相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients
Margarita Garcia et al.
HUMAN GENE THERAPY (2019)
SnapShot: Cancer Immunotherapy with Oncolytic Viruses
Shashi Gujar et al.
CELL (2019)
Viral oncolytic immunotherapy in the war on cancer: Infection control considerations
Elizabeth V. Robilotti et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2019)
Use of stem cells as carriers of oncolytic viruses for cancer treatment
Elham Zendedel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Guillem Pascual-Pasto et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells
Masaya Igase et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2019)
Updates to the antitumor mechanism of oncolytic virus
Yang Bai et al.
THORACIC CANCER (2019)
A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression
Susanne G. Warner et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy
Li-Li Huang et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2019)
Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells
Arthur Dyer et al.
CANCER RESEARCH (2019)
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2
Yang Wang et al.
HUMAN GENE THERAPY (2019)
A cautionary note on the selectivity of oncolytic poxviruses
Bingtao Tang et al.
ONCOLYTIC VIROTHERAPY (2019)
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results
Vignesh T. Packiam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
Yoshiki Hirooka et al.
BMC CANCER (2018)
Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells In Vitro and In Vivo
Carolini Kaid et al.
CANCER RESEARCH (2018)
Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Teruhide Yamaguchi et al.
CURRENT CANCER DRUG TARGETS (2018)
Fighting Cancer with Viruses: Oncolytic Virus Therapy in China
Ding Wei et al.
HUMAN GENE THERAPY (2018)
Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy
Zi J. Wu et al.
HUMAN GENE THERAPY (2018)
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
Michael P. O'Leary et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma
Jason Chesney et al.
MELANOMA RESEARCH (2018)
Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones
Nikolas Tim Martin et al.
MOLECULAR THERAPY (2018)
Dimethyl fumarate potentiates oncolytic virotherapy through NF-kappa B inhibition
Mohammed Selman et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple- negative breast cancer to immune checkpoint therapy
Marie-Claude Bourgeois-Daigneault et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Adel Samson et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer
Cheng Hu et al.
CELL DEATH & DISEASE (2018)
Transforming the prostatic tumor microenvironment with oncolytic virotherapy
Matthew J. Atherton et al.
ONCOIMMUNOLOGY (2018)
Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer
Audrey H. Choi et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection
Michael P. O'Leary et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
In Vivo Estimation of Oncolytic Virus Populations within Tumors
Mi-Yeon Jung et al.
CANCER RESEARCH (2018)
The advent of oncolytic virotherapy in oncology: The Rigvir® story
Peteris Alberts et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma
Sarah Abdullahi et al.
JOURNAL OF VIROLOGY (2018)
Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice
Marcin Komorowski et al.
VIRUSES-BASEL (2018)
Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus
Euna Cho et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
Amanda Rosewell Shaw et al.
FRONTIERS IN IMMUNOLOGY (2018)
A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients
Margarita Garcia et al.
Human Gene Therapy Clinical Development (2018)
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells
Joshua D. Freedman et al.
CANCER RESEARCH (2018)
DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
Xiao Xiao et al.
NATURE COMMUNICATIONS (2018)
Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins
Xiao-Qin Liu et al.
DRUG DELIVERY (2018)
The emerging role of oncolytic virus therapy against cancer
Luke Russell et al.
CHINESE CLINICAL ONCOLOGY (2018)
New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy
Kenneth Lundstrom
BIOLOGICS-TARGETS & THERAPY (2018)
Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3
Zahid M. Delwar et al.
CANCER RESEARCH (2018)
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Praveen K. Bommareddy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
The safety of talimogene laherparepvec for the treatment of advanced melanoma
Alexandra Gangi et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors
Jiahu Wang et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Designing and building oncolytic viruses
Justin Maroun et al.
FUTURE VIROLOGY (2017)
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
David E. Cohn et al.
GYNECOLOGIC ONCOLOGY (2017)
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
A. Dispenzieri et al.
LEUKEMIA (2017)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial
Karsten Geletneky et al.
MOLECULAR THERAPY (2017)
A practical guide to the handling and administration of talimogene laherparepvec in Europe
Kevin J. Harrington et al.
ONCOTARGETS AND THERAPY (2017)
Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors
Alicia M Waters et al.
Human Gene Therapy Clinical Development (2017)
Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma
Muneyoshi Futami et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Prospects for combined use of oncolytic viruses and CAR T-cells
Adam Ajina et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102-Support for clinical studies on advanced cancer treatment
Lukasz Kuryk et al.
PLOS ONE (2017)
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
Chun-Yu Chen et al.
SCIENTIFIC REPORTS (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol
Jacek Hajda et al.
BMC CANCER (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients
Keri A. Streby et al.
CLINICAL CANCER RESEARCH (2017)
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
Laetitia Fend et al.
CANCER RESEARCH (2017)
Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma
Patricia A. Corrigan et al.
ANNALS OF PHARMACOTHERAPY (2017)
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
Hong Jiang et al.
CANCER RESEARCH (2017)
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Mee Y. Bartee et al.
CANCER RESEARCH (2017)
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer
Kyung Hee Jung et al.
CANCER LETTERS (2017)
Recent advances in genetic modification of adenovirus vectors for cancer treatment
Yuki Yamamoto et al.
CANCER SCIENCE (2017)
Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy
Frederick J. Kohlhapp et al.
CLINICAL CANCER RESEARCH (2016)
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination
Aline Baldo et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy
Weizhou Hou et al.
CANCER CELL (2016)
Oncolytic virus therapy: A new era of cancer treatment at dawn
Hiroshi Fukuhara et al.
CANCER SCIENCE (2016)
Defending against smallpox: a focus on vaccines
Emily A. Voigt et al.
EXPERT REVIEW OF VACCINES (2016)
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers
Stephanie Downs-Canner et al.
MOLECULAR THERAPY (2016)
Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice
Sangeet Lal et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2016)
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS
Lianwen Zhang et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2016)
Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers
Tien V. Nguyen et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Oncolytic virotherapy for pediatric malignancies: future prospects
Alicia M. Waters et al.
ONCOLYTIC VIROTHERAPY (2016)
YVEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
Rozanne Arulanandam et al.
CANCER CELL (2015)
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park et al.
MOLECULAR THERAPY (2015)
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients
Timothy P. Cripe et al.
MOLECULAR THERAPY (2015)
First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
Herbert J. Zeh et al.
MOLECULAR THERAPY (2015)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors
Adam W. Studebaker et al.
NEURO-ONCOLOGY (2015)
Establishing the Lysine-rich Protein CEST Reporter Gene as a CEST MR Imaging Detector for Oncolytic Virotherapy
Christian T. Farrar et al.
RADIOLOGY (2015)
Oncolytic parvoviruses: from basic virology to clinical applications
Antonio Marchini et al.
VIROLOGY JOURNAL (2015)
Oncolytic viruses: From bench to bedside with a focus on safety
Pascal R. A. Buijs et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Safety Profiles and Antitumor Efficacy of Oncolytic Adenovirus Coated with Bioreducible Polymer in the Treatment of a CAR Negative Tumor Model
Soo-Jung Jung et al.
BIOMACROMOLECULES (2015)
Safety and Efficacy of VCN-01, an Oncolytic Adenovirus Combining Fiber HSG-Binding Domain Replacement with RGD and Hyaluronidase Expression
Alba Rodriguez-Garcia et al.
CLINICAL CANCER RESEARCH (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schoenfeld et al.
MOLECULAR THERAPY (2015)
Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients
Assia L. Angelova et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2015)
In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models
Y. Jing et al.
GENE THERAPY (2014)
Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy
Michelle Cronin et al.
MOLECULAR THERAPY (2014)
A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses
James M. Markert et al.
MOLECULAR THERAPY (2014)
Preclinical Safety Assessment of Ad[I/PPT-E1A], a Novel Oncolytic Adenovirus for Prostate Cancer
Ellen Schenk et al.
HUMAN GENE THERAPY CLINICAL DEVELOPMENT (2014)
Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults
Kimberly P. Kicielinski et al.
MOLECULAR THERAPY (2014)
Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer
Hideki Kasuya et al.
HEPATO-GASTROENTEROLOGY (2014)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
Oncolytic measles virus strains as novel anticancer agents
Pavlos Msaouel et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Amalgamating Oncolytic Viruses to Enhance Their Safety, Consolidate Their Killing Mechanisms, and Accelerate Their Spread
Camilo Ayala-Breton et al.
MOLECULAR THERAPY (2013)
Model-based rational design of an oncolytic virus with improved therapeutic potential
Fabrice Le Boeuf et al.
NATURE COMMUNICATIONS (2013)
Evolution of oncolytic adenovirus for cancer treatment
Joung-Woo Choi et al.
ADVANCED DRUG DELIVERY REVIEWS (2012)
Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
Karsten Geletneky et al.
BMC CANCER (2012)
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
Sari Pesonen et al.
CANCER RESEARCH (2012)
Combined Fiber Modifications Both to Target αvβ6 and Detarget the Coxsackievirus-Adenovirus Receptor Improve Virus Toxicity Profiles In Vivo but Fail to Improve Antitumoral Efficacy Relative to Adenovirus Serotype 5
Lynda Coughlan et al.
HUMAN GENE THERAPY (2012)
An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance
Vincenzo Cerullo et al.
MOLECULAR THERAPY (2012)
Oncolytic virotherapy
Stephen J. Russell et al.
NATURE BIOTECHNOLOGY (2012)
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients
Kenneth H. Kim et al.
HUMAN GENE THERAPY (2011)
Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy
Han Yuen Lam et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a mouse squamous cell carcinoma model
Aya Saito et al.
JOURNAL OF GENE MEDICINE (2011)
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Caroline J. Breitbach et al.
NATURE (2011)
Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis et al.
CANCER RESEARCH (2010)
A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases
Kristopher J. Kimball et al.
CLINICAL CANCER RESEARCH (2010)
REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
Charles Comins et al.
CLINICAL CANCER RESEARCH (2010)
Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
Sunil K. Geevarghese et al.
HUMAN GENE THERAPY (2010)
Synergistic Interaction Between Oncolytic Viruses Augments Tumor Killing
Fabrice Le Boeuf et al.
MOLECULAR THERAPY (2010)
A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy
Na Wei et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Phase Ib Trial of Oncolytic Herpes Virus G207 shows safety of Multiple Injections and Documents Viral Replication
Manish K. Aghi et al.
MOLECULAR THERAPY (2009)
Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy
Kaitlyn J. Kelly et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas
Peter Forsyth et al.
MOLECULAR THERAPY (2008)
History of oncolytic viruses: Genesis to genetic engineering
Elizabeth Kelly et al.
MOLECULAR THERAPY (2007)
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C. C. Hu et al.
CLINICAL CANCER RESEARCH (2006)
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma
Yasushi Fujimoto et al.
ACTA OTO-LARYNGOLOGICA (2006)
Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus
H Ochiai et al.
CLINICAL CANCER RESEARCH (2006)
Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer
SI Kohno et al.
UROLOGY (2005)
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial
Wei Lu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2004)
HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival
S Harrow et al.
GENE THERAPY (2004)
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates
S Varghese et al.
HUMAN GENE THERAPY (2001)
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
J Nemunaitis et al.
GENE THERAPY (2001)
Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in Aotus
T Todo et al.
MOLECULAR THERAPY (2000)
分享论文
